Rufinamide is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in paediatric patients 1 year of age and older and in adults.
According to IQVIA, US sales of Rufinamide Tablets, 200mg and 400mg, were approximately $285 million in the 12 months ending April 2021.
“We are proud to be among the first wave of generics to provide this important medicine,” said Brian Hoffmann, President of Hikma Generics. “Hikma also markets Rufinamide Oral Suspension and we are pleased to add this new formulation to our portfolio. This launch demonstrates our ability to successfully deliver on our pipeline and launch new products, improving patients’ access to high-quality generic medicines.”
Date: Jun 24, 2021
Share this news: